Tumor hypoxia is often associated with resistance to chemotherapy. Multidrug resistance
type 1 (MDR1) protein is a member of the adenosine triphosphate binding cassette (ABC) …

MISO in vitro into EMT6 cells was investigated at the dissolved oxygen concentrations of 0, 1
x to3, 5 x 103, 5 x 10" and 2 x 105 ppm. Biodistribution performed at 1, 5, 10, 20 and 40 min …

BACKGROUND: Cu-diacetyl-bis (N4-methylthiosemicarbazone)[Cu-ATSM] is a potential
marker for tumor hypoxia that has been under evaluation for clinical use. In this study, we …

Technetium-99m sestamibi is a transport substrate recognised by the multidrug-resistant P-
glycoprotein (Pgp). To test whether 99m Tc-sestamibi efflux is enhanced in breast …

99mTc-methoxyisobutylisonitrile (99mTc-MIBI) has been suggested as a tracer for the
scintigraphic detection of multidrug resistance (MDR). The aim of this study was to compare …

We compared the imaging characteristics and hypoxia selectivity of 4 hypoxia PET
radiotracers (18F-fluoromisonidazole [18F-FMISO], 18F-flortanidazole [18F-HX4], 18F …

It was reported recently that 99mTc-hexakis-2-methoxyisobutyl isonitrile (MIBI) uptake is
drastically reduced in cancer cells that express the multidrug resistance (MDR) product, Pgp …

The hypoxia PET tracer 64Cu-diacetyl-bis (N 4-methylthiosemicarbazonate)(64Cu-ATSM)
has shown promising results in clinical studies. However, concerns have been raised with …

P-glycoprotein, the membrane transporter that is a mechanism of multidrug resistance
(MDR) in tumors. This has been further inves tigated in the rat mammary carcinoma cell line …

Early diagnosis of multidrug-resistance (MDR) development is extremely important for the
judicious choice of treatment protocols in breast cancer chemotherapy. In this study, the …